Results 51 to 60 of about 65,110 (152)

Current and potential use of GLP-1R agonists: beyond type 2 diabetes

Revista Mexicana de Endocrinología, Metabolismo y Nutrición
Intestinal incretins, glucagon-like peptide 1 (GLP-1), and gastric insulinotropic peptide, which are released after food ingestion, have glucoregulatory effects, which is why, in recent years, pharmacological agents with an impact similar to incretins ...
Graciela Zambrano-Galván, Ángel González-Romero, Miguel A. Reyes-Romero, Abelardo Camacho-Luis   +3 more
doaj   +1 more source

Curcumin alone not combined with piperine exerts cardioprotective effects in pressure-overload rats by increasing glucagon-like peptide-1 receptor signaling and additional properties

Journal of Traditional and Complementary Medicine
Background and aim: Curcumin has shown significant cardiovascular protective effects. However, the low bioavailability limits its practical application. As a natural bioenhancer, piperine is expected to increase the bioavailability of curcumin, and then,
Xiao-jie Bai, Jun-tao Hao, Qi-long Feng, Chen-meng Guo, Min Pang, Jia Li, Jin Wang, Jian-feng Xing   +7 more
doaj   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists and Risk of Uveitis

JAMA Ophthalmology
ImportanceEmerging evidence suggests that glucagon-like peptide-1 receptor agonists (GLP-1RAs), commonly used for glycemic control in diabetes, may possess anti-inflammatory properties. Understanding their potential protective role against uveitis could provide insights into novel therapeutic strategies.ObjectiveTo evaluate whether being prescribed a ...
Mohan, Nitesh, Srivastava, Sunil K., Schulgit, Matthew J., Nowacki, Amy S., Kaelber, David C., Sharma, Sumit   +5 more
openaire   +2 more sources

The role of glucagon-like peptide-1 receptor agonists (GLP1-RAs) in the management of the hypertensive patient with metabolic syndrome: a position paper from the Korean society of hypertension

Clinical Hypertension
Obesity is the one of the most important components of metabolic syndrome. Because obesity related hypertension accounts for two thirds of essential hypertension, managing obesity and metabolic syndrome is a crucial task in the management of hypertension.
Hae Young Lee, Seung-Hyun Ko, Sungjoon Park, Kyuho Kim, Song-Yi Kim, In-Jeong Cho, Eun Joo Cho, Hyeon Chang Kim, Jae-Hyeong Park, Sung Kee Ryu, Min Kyong Moon, Sang-Hyun Ihm, the Korean Society of Hypertension   +12 more
doaj   +1 more source

Glucagon-like Peptide-1 Receptor Agonists and the Perioperative Patient. [PDF]

AORN J
Fischer L.
europepmc   +1 more source

Are Glucagon-Like Peptide-1 Receptor Agonists Suitable for Secondary Stroke Prevention? [PDF]

J Clin Neurol
Kwon HS, Koh SH.
europepmc   +1 more source

Trends in glucagon-like peptide-1 receptor agonist utilization and expenditure in Croatia. [PDF]

J Int Med Res
Belančić A, Kučan Štiglić M, Fajkić A, Jelaković A, Pećin I, Reiner Ž, Jelaković B, Vitezić D.   +7 more
europepmc   +1 more source

Glucagon-Like Peptide-1 Receptor Agonist and Hyponatremia: A Potential Association. [PDF]

JACC Case Rep
Yeo YH, Dixon SR.
europepmc   +1 more source

Prescription Sequence Symmetry Analysis of Glucagon-Like Peptide-1 Receptor Agonists and Neuropsychiatric Conditions. [PDF]

Clin Pharmacol Ther
Alfonso Arvez MJ, Wade S, Goordeen D, Ilomäki J, Cross AJ, Langiu M, Tan GSQ.   +6 more
europepmc   +1 more source

Pre-operative gastric volume measurement and glucagon-like peptide-1 receptor agonists. [PDF]

Anaesthesia
Lim ZJ, Dubey H, Munoz LM.
europepmc   +1 more source